See more : BNP Paribas SA (BNPQF) Income Statement Analysis – Financial Results
Complete financial analysis of RedHill Biopharma Ltd. (RDHL) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of RedHill Biopharma Ltd., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Fitvia Corp. (BRZV) Income Statement Analysis – Financial Results
- Deutsche Post AG (DHL.DE) Income Statement Analysis – Financial Results
- Cathay Pacific Airways Limited (0293.HK) Income Statement Analysis – Financial Results
- Regency Silver Corp. (RSMXF) Income Statement Analysis – Financial Results
- Amigo Technology Inc. (6241.TWO) Income Statement Analysis – Financial Results
RedHill Biopharma Ltd. (RDHL)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.redhillbio.com
About RedHill Biopharma Ltd.
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204, which is in Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), an SK2 selective inhibitor, which has completed Phase 2 study to treat patients with SARS-CoV-2 severe COVID-19 pneumonia, in Phase 2 study to treat advanced unresectable cholangiocarcinoma, and in investigator-sponsored Phase 2 study to treat prostate cancer; RHB-107, which is in Phase 2/3 study to treat outpatients infected with COVID-19 disease, and preclinical evaluation study to treat advanced unresectable cholangiocarcinoma, as well as has completed Phase 2 study to treat gastrointestinal and other solid tumors; RHB-104, which is in Phase 3 studies for Crohn's disease; RHB-102 (Bekinda) that is in Phase 3 studies for acute gastroenteritis and gastritis, and has completed Phase 2 studies for irritable bowel syndrome with diarrhea; and RHB-106, an encapsulated formulation for bowel preparation, which is preparing for Phase 2/3 study. RedHill Biopharma Ltd. was incorporated in 2009 and is headquartered in Tel Aviv, Israel.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 6.51M | 61.80M | 85.76M | 64.36M | 6.29M | 8.36M | 4.01M | 101.00K | 3.00K | 7.01M | 12.00K | 16.00K | 23.00K | 0.00 |
| Cost of Revenue | 3.46M | 33.34M | 49.41M | 36.89M | 2.26M | 2.84M | 2.13M | 30.54M | 22.00M | 1.05M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 3.05M | 28.46M | 36.35M | 27.47M | 4.03M | 5.52M | 1.88M | -30.44M | -22.00M | 5.96M | 12.00K | 16.00K | 23.00K | 0.00 |
| Gross Profit Ratio | 46.89% | 46.06% | 42.39% | 42.68% | 64.09% | 66.06% | 46.94% | -30,140.59% | -733,300.00% | 85.03% | 100.00% | 100.00% | 100.00% | 0.00% |
| Research & Development | 3.52M | 7.28M | 29.50M | 16.49M | 17.42M | 24.86M | 32.97M | 25.24M | 17.77M | 12.70M | 8.10M | 6.46M | 5.41M | 736.00K |
| General & Administrative | 28.88M | 54.97M | 76.60M | 25.38M | 11.48M | 7.51M | 8.03M | 5.40M | 4.13M | 4.01M | 2.68M | 2.60M | 2.48M | 518.00K |
| Selling & Marketing | 2.10M | 9.06M | 11.39M | 49.29M | 18.33M | 12.49M | 12.01M | 1.56M | 1.39M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 30.98M | 64.03M | 87.99M | 74.66M | 29.81M | 19.99M | 20.04M | 5.40M | 4.13M | 4.01M | 2.68M | 2.60M | 2.48M | 518.00K |
| Other Expenses | -44.06M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 845.00K | 0.00 | 100.00K | -100.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | -9.56M | 71.31M | 117.49M | 91.15M | 47.23M | 44.85M | 53.85M | 30.64M | 22.01M | 16.61M | 10.78M | 9.06M | 7.90M | 1.73M |
| Cost & Expenses | -6.10M | 104.64M | 166.89M | 128.04M | 49.49M | 47.69M | 55.98M | 30.64M | 22.01M | 17.66M | 10.78M | 9.06M | 7.90M | 1.73M |
| Interest Income | 93.76K | 140.00K | 51.00K | 270.00K | 1.34M | 678.00K | 6.51M | 1.55M | 1.12M | 319.00K | 158.00K | 119.00K | 14.00K | 2.00K |
| Interest Expense | 367.00K | 41.33M | 16.57M | 12.76M | 438.00K | 167.00K | 77.00K | 375.00K | 212.00K | 383.00K | 14.00K | 1.48M | 65.00K | 876.00K |
| Depreciation & Amortization | 1.99M | 8.12M | 18.16M | 8.81M | 1.22M | 89.71K | 81.57K | 44.14K | 36.00K | 27.00K | 24.00K | 24.00K | 15.00K | -63.00K |
| EBITDA | 26.31M | -42.84M | -63.03M | -54.94M | -40.78M | -38.60M | -45.79M | -30.50M | -21.87M | -10.62M | -10.75M | -9.02M | -7.86M | -2.55M |
| EBITDA Ratio | 403.94% | -56.00% | -73.46% | -84.94% | -646.21% | -461.28% | -1,132.67% | -28,664.36% | -694,733.33% | -146.86% | -88,250.00% | -56,837.50% | -36,456.52% | 0.00% |
| Operating Income | 12.63M | -42.84M | -81.14M | -63.68M | -43.20M | -39.33M | -51.97M | -30.54M | -22.00M | -10.65M | -10.77M | -9.04M | -7.87M | -1.73M |
| Operating Income Ratio | 193.95% | -69.33% | -94.61% | -98.95% | -686.71% | -470.47% | -1,297.03% | -30,240.59% | -733,400.00% | -151.80% | -89,766.67% | -56,500.00% | -34,230.43% | 0.00% |
| Total Other Income/Expenses | 11.32M | -28.83M | -16.61M | -12.49M | 897.00K | 511.00K | 6.43M | 1.17M | 812.00K | -64.00K | 144.00K | -1.29M | -7.63M | -811.00K |
| Income Before Tax | 23.95M | -71.67M | -97.74M | -76.17M | -42.30M | -38.82M | -45.54M | -29.37M | -21.09M | -10.71M | -10.63M | -10.33M | -15.50M | -2.54M |
| Income Before Tax Ratio | 367.75% | -115.97% | -113.98% | -118.36% | -672.45% | -464.35% | -1,136.61% | -29,079.21% | -703,000.00% | -152.71% | -88,566.67% | -64,537.50% | -67,404.35% | 0.00% |
| Income Tax Expense | 0.00 | -12.42M | 16.57M | 12.84M | 1.33M | 727.00K | 6.29M | 1.27M | 900.00K | 222.00K | 142.00K | 1.29M | 7.63M | 874.00K |
| Net Income | 23.92M | -59.25M | -114.31M | -89.02M | -43.63M | -38.82M | -45.54M | -29.37M | -21.09M | -10.71M | -10.63M | -10.33M | -15.50M | -2.54M |
| Net Income Ratio | 367.19% | -95.87% | -133.30% | -138.31% | -693.59% | -464.35% | -1,136.61% | -29,079.21% | -703,000.00% | -152.71% | -88,566.67% | -64,537.50% | -67,404.35% | 0.00% |
| EPS | 3.69 | -38.27 | -98.27 | -97.75 | -58.78 | -68.00 | -104.00 | -94.96 | -76.13 | -49.47 | -68.15 | -80.00 | -128.96 | -19.35 |
| EPS Diluted | 3.69 | -38.27 | -98.27 | -97.75 | -58.78 | -68.00 | -104.00 | -92.00 | -75.51 | -49.12 | -68.15 | -78.53 | -128.96 | -19.35 |
| Weighted Avg Shares Out | 6.48M | 1.55M | 1.16M | 910.69K | 742.30K | 570.88K | 437.92K | 309.30K | 277.04K | 216.53K | 155.95K | 129.08K | 120.22K | 131.49K |
| Weighted Avg Shares Out (Dil) | 6.48M | 1.55M | 1.16M | 910.69K | 742.30K | 570.88K | 437.92K | 319.24K | 279.29K | 218.06K | 155.95K | 131.49K | 120.22K | 131.49K |
RedHill Biopharma shares jump as Ebola treatment shows promise
RedHill Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
RedHill Announces New, Non-Dilutive External Funding of Entire RHB-107 COVID-19 300-Patient Phase 2 Study
Bill Gross says beaten-down mortgage plays may thrive — and offer huge yields
These advisers say markets are expecting unrealistic outcomes. Here are some alternatives.
Why Is Redhill Biopharma (RDHL) Stock Down 27% Today?
RedHill Biopharma (RDHL) gained 216% after FDA approvals: Buy Now!
5 Investors Betting Big on RedHill Biopharma (RDHL) Stock
RedHill Biopharma Announces FDA Grant of 5-Year U.S. Market Exclusivity for Talicia® with IP Protection Running to 2034
RedHill Biopharma Announces the Transfer of its Listing to The Nasdaq Capital Market
Source: https://incomestatements.info
Category: Stock Reports